View source for 9giv


==Structure of the human mitochondrial pyruvate carrier inhibited by a UK5099-derivative==
<StructureSection load='9giv' size='340' side='right'caption='[[9giv]], [[Resolution|resolution]] 3.65&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[9giv]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9GIV OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9GIV FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.65&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1IL4:(~{E})-2-cyano-3-[5-(2-nitrophenyl)furan-2-yl]prop-2-enoic+acid'>A1IL4</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9giv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9giv OCA], [https://pdbe.org/9giv PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9giv RCSB], [https://www.ebi.ac.uk/pdbsum/9giv PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9giv ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/MPC1L_HUMAN MPC1L_HUMAN] Mediates the uptake of pyruvate into mitochondria.<ref>PMID:27317664</ref> 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
The mitochondrial pyruvate carrier transports pyruvate, produced by glycolysis from sugar molecules, into the mitochondrial matrix, as a crucial transport step in eukaryotic energy metabolism. The carrier is a drug target for the treatment of cancers, diabetes mellitus, neurodegeneration, and metabolic dysfunction-associated steatotic liver disease. We have solved the structure of the human MPC1L/MPC2 heterodimer in the inward- and outward-open states by cryo-electron microscopy, revealing its alternating access rocker-switch mechanism. The carrier has a central binding site for pyruvate, which contains an essential lysine and histidine residue, important for its DeltapH-dependent transport mechanism. We have also determined the binding poses of three chemically distinct inhibitor classes, which exploit the same binding site in the outward-open state by mimicking pyruvate interactions and by using aromatic stacking interactions.

Molecular basis of pyruvate transport and inhibition of the human mitochondrial pyruvate carrier.,Sichrovsky M, Lacabanne D, Ruprecht JJ, Rana JJ, Stanik K, Dionysopoulou M, Sowton AP, King MS, Jones SA, Cooper L, Hardwick SW, Paris G, Chirgadze DY, Ding S, Fearnley IM, Palmer SM, Pardon E, Steyaert J, Leone V, Forrest LR, Tavoulari S, Kunji ERS Sci Adv. 2025 Apr 18;11(16):eadw1489. doi: 10.1126/sciadv.adw1489. Epub 2025 Apr , 18. PMID:40249800<ref>PMID:40249800</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 9giv" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Synthetic construct]]
[[Category: Chirgadze DY]]
[[Category: Cooper L]]
[[Category: Ding S]]
[[Category: Dionysopoulou M]]
[[Category: Fearnley IMF]]
[[Category: Forrest LR]]
[[Category: Hardwick SW]]
[[Category: Jones S]]
[[Category: King MS]]
[[Category: Kunji ERS]]
[[Category: Lacabanne D]]
[[Category: Leone V]]
[[Category: Palmer S]]
[[Category: Pardon E]]
[[Category: Paris G]]
[[Category: Rana JJ]]
[[Category: Ruprecht JJ]]
[[Category: Sichrovsky M]]
[[Category: Sowton AP]]
[[Category: Stanik K]]
[[Category: Steyaert J]]
[[Category: Tavoulari S]]